Leavenworth’s contributions bridge laboratory research with clinical applications, paving the way for innovative cancer immunotherapies. With 50 publications and ongoing research, her work continues ...

Representatives from four leading companies highlight emerging basic and clinical research that drives renewed optimism.

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from ...

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from manageable conditions to fatal diseases.

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein ...

After hours: February 28 at 7:54:43 PM EST ...